VERTEX PHARMACEUTICALS INC (1VRTX.MI) Fundamental Analysis & Valuation

BIT:1VRTX • US92532F1003

Current stock price

334.7 EUR
-2.05 (-0.61%)
Last:

This 1VRTX.MI fundamental analysis includes valuation metrics, fair value assessment, financial health analysis, profitability trends, growth metrics and dividend sustainability analysis.

8

1. 1VRTX.MI Profitability Analysis

1.1 Basic Checks

  • In the past year 1VRTX was profitable.
  • 1VRTX had a positive operating cash flow in the past year.
  • 1VRTX had positive earnings in 4 of the past 5 years.
  • Of the past 5 years 1VRTX 4 years had a positive operating cash flow.
1VRTX.MI Yearly Net Income VS EBIT VS OCF VS FCF1VRTX.MI Yearly Net Income VS EBIT VS OCF VS FCFYearly Net Income VS EBIT VS OCF VS FCF 2016 2017 2018 2019 2020 2021 2022 2023 2024 0 1B 2B 3B 4B

1.2 Ratios

  • Looking at the Return On Assets, with a value of 15.13%, 1VRTX belongs to the top of the industry, outperforming 86.84% of the companies in the same industry.
  • 1VRTX has a Return On Equity of 21.18%. This is amongst the best in the industry. 1VRTX outperforms 88.16% of its industry peers.
  • Looking at the Return On Invested Capital, with a value of 16.69%, 1VRTX belongs to the top of the industry, outperforming 90.79% of the companies in the same industry.
  • 1VRTX had an Average Return On Invested Capital over the past 3 years of 18.67%. This is significantly above the industry average of 11.89%.
Industry RankSector Rank
ROA 15.13%
ROE 21.18%
ROIC 16.69%
ROA(3y)10.62%
ROA(5y)14.47%
ROE(3y)13.73%
ROE(5y)19.12%
ROIC(3y)18.67%
ROIC(5y)19.24%
1VRTX.MI Yearly ROA, ROE, ROIC1VRTX.MI Yearly ROA, ROE, ROICYearly ROA, ROE, ROIC 2016 2017 2018 2019 2020 2021 2022 2023 2024 0 10 20 30 40

1.3 Margins

  • Looking at the Profit Margin, with a value of 31.86%, 1VRTX belongs to the top of the industry, outperforming 86.84% of the companies in the same industry.
  • 1VRTX has a better Operating Margin (38.77%) than 92.11% of its industry peers.
  • In the last couple of years the Operating Margin of 1VRTX has grown nicely.
  • Looking at the Gross Margin, with a value of 86.11%, 1VRTX is in the better half of the industry, outperforming 75.00% of the companies in the same industry.
  • In the last couple of years the Gross Margin of 1VRTX has remained more or less at the same level.
Industry RankSector Rank
OM 38.77%
PM (TTM) 31.86%
GM 86.11%
OM growth 3Y2.79%
OM growth 5Y6.75%
PM growth 3YN/A
PM growth 5YN/A
GM growth 3Y-0.74%
GM growth 5Y-0.17%
1VRTX.MI Yearly Profit, Operating, Gross Margins1VRTX.MI Yearly Profit, Operating, Gross MarginsYearly Profit, Operating, Gross Margins 2016 2017 2018 2019 2020 2021 2022 2023 2024 0 20 40 60 80

More info and screens

ROAROEROICOperating and Profit MarginShow most profitable peers

7

2. 1VRTX.MI Health Analysis

2.1 Basic Checks

  • The Return on Invested Capital (ROIC) is well above the Cost of Capital (WACC), so 1VRTX is creating value.
  • 1VRTX has less shares outstanding than it did 1 year ago.
  • Compared to 5 years ago, 1VRTX has less shares outstanding
  • 1VRTX has a better debt/assets ratio than last year.
1VRTX.MI Yearly Shares Outstanding1VRTX.MI Yearly Shares OutstandingYearly Shares Outstanding 2016 2017 2018 2019 2020 2021 2022 2023 2024 50M 100M 150M 200M 250M
1VRTX.MI Yearly Total Debt VS Total Assets1VRTX.MI Yearly Total Debt VS Total AssetsYearly Total Debt VS Total Assets 2016 2017 2018 2019 2020 2021 2022 2023 2024 5B 10B 15B 20B

2.2 Solvency

  • 1VRTX has no outstanding debt. Therefor its Debt/Equity and Debt/FCF ratios are 0 and belong to the best of the industry.
Industry RankSector Rank
Debt/Equity 0
Debt/FCF 0
Altman-Z N/A
ROIC/WACC1.73
WACC9.67%
1VRTX.MI Yearly LT Debt VS Equity VS FCF1VRTX.MI Yearly LT Debt VS Equity VS FCFYearly LT Debt VS Equity VS FCF 2016 2017 2018 2019 2020 2021 2022 2023 2024 0 5B 10B 15B

2.3 Liquidity

  • A Current Ratio of 2.52 indicates that 1VRTX has no problem at all paying its short term obligations.
  • 1VRTX has a Current ratio (2.52) which is comparable to the rest of the industry.
  • 1VRTX has a Quick Ratio of 2.16. This indicates that 1VRTX is financially healthy and has no problem in meeting its short term obligations.
  • 1VRTX's Quick ratio of 2.16 is in line compared to the rest of the industry. 1VRTX outperforms 59.21% of its industry peers.
Industry RankSector Rank
Current Ratio 2.52
Quick Ratio 2.16
1VRTX.MI Yearly Current Assets VS Current Liabilites1VRTX.MI Yearly Current Assets VS Current LiabilitesYearly Current Assets VS Current Liabilites 2016 2017 2018 2019 2020 2021 2022 2023 2024 5B 10B

More info and screens

WACCDebt/EquityHow to determine the health of a companyAltman-Z scoreShow peers with great health

8

3. 1VRTX.MI Growth Analysis

3.1 Past

  • The Earnings Per Share has grown by an impressive 7966.67% over the past year.
  • 1VRTX shows a very negative growth in Earnings Per Share. Measured over the last years, the EPS has been decreasing by -44.14% yearly.
  • 1VRTX shows quite a strong growth in Revenue. In the last year, the Revenue has grown by 10.46%.
  • Measured over the past years, 1VRTX shows a very strong growth in Revenue. The Revenue has been growing by 21.50% on average per year.
EPS 1Y (TTM)7966.67%
EPS 3Y-71.86%
EPS 5Y-44.14%
EPS Q2Q%135.23%
Revenue 1Y (TTM)10.46%
Revenue growth 3Y13.31%
Revenue growth 5Y21.5%
Sales Q2Q%12.06%

3.2 Future

  • The Earnings Per Share is expected to grow by 150.73% on average over the next years. This is a very strong growth
  • Based on estimates for the next years, 1VRTX will show a quite strong growth in Revenue. The Revenue will grow by 10.01% on average per year.
EPS Next Y6256.61%
EPS Next 2Y749.77%
EPS Next 3Y329.69%
EPS Next 5Y150.73%
Revenue Next Year10.03%
Revenue Next 2Y9.8%
Revenue Next 3Y9.48%
Revenue Next 5Y10.01%

3.3 Evolution

  • The EPS growth rate is accelerating: in the next years the growth will be better than in the last years.
  • Although the future Revenue growth is still strong, it is not able to hold up the even more excellent growth rate of the past years.
1VRTX.MI Yearly Revenue VS Estimates1VRTX.MI Yearly Revenue VS EstimatesYearly Revenue VS Estimates 2015 2016 2017 2018 2019 2020 2021 2022 2023 2024 2025 2026 2027 2028 2029 2030 2031 2032 5B 10B 15B 20B
1VRTX.MI Yearly EPS VS Estimates1VRTX.MI Yearly EPS VS EstimatesYearly EPS VS Estimates 2015 2016 2017 2018 2019 2020 2021 2022 2023 2024 2025 2026 2027 2028 2029 2030 2031 2032 0 10 20 30

More info and screens

Find the best growth stocksShow best growing peers

6

4. 1VRTX.MI Valuation Analysis

4.1 Price/Earnings Ratio

  • A Price/Earnings ratio of 23.19 indicates a rather expensive valuation of 1VRTX.
  • Compared to the rest of the industry, the Price/Earnings ratio of 1VRTX indicates a rather cheap valuation: 1VRTX is cheaper than 80.26% of the companies listed in the same industry.
  • Compared to an average S&P500 Price/Earnings ratio of 25.35, 1VRTX is valued at the same level.
  • Based on the Price/Forward Earnings ratio of 18.76, the valuation of 1VRTX can be described as rather expensive.
  • Based on the Price/Forward Earnings ratio, 1VRTX is valued cheaper than 81.58% of the companies in the same industry.
  • Compared to an average S&P500 Price/Forward Earnings ratio of 22.61, 1VRTX is valued at the same level.
Industry RankSector Rank
PE 23.19
Fwd PE 18.76
1VRTX.MI Price Earnings VS Forward Price Earnings1VRTX.MI Price Earnings VS Forward Price Earnings ChartPrice Earnings - Forward Price Earnings PE FPE 10 20 30 40 50

4.2 Price Multiples

  • 76.32% of the companies in the same industry are more expensive than 1VRTX, based on the Enterprise Value to EBITDA ratio.
  • Based on the Price/Free Cash Flow ratio, 1VRTX is valued a bit cheaper than the industry average as 78.95% of the companies are valued more expensively.
Industry RankSector Rank
P/FCF 28.78
EV/EBITDA 20.39
1VRTX.MI Per share data1VRTX.MI EPS, Sales, OCF, FCF, BookValue per sharePer Share Data Per Share 10 20 30 40 50

4.3 Compensation for Growth

  • 1VRTX's low PEG Ratio(NY), which compensates the Price/Earnings for growth, indicates a rather cheap valuation of the company.
  • The excellent profitability rating of 1VRTX may justify a higher PE ratio.
  • A more expensive valuation may be justified as 1VRTX's earnings are expected to grow with 329.69% in the coming years.
PEG (NY)0
PEG (5Y)N/A
EPS Next 2Y749.77%
EPS Next 3Y329.69%

More info and screens

Price/EarningsPrice/FCFFCF per shareEV/EBITDAPEG RATIOShow best valued peers

0

5. 1VRTX.MI Dividend Analysis

5.1 Amount

  • No dividends for 1VRTX!.
Industry RankSector Rank
Dividend Yield N/A

More info and screens

Find the best dividend stocksShow peers with best dividend

1VRTX.MI Fundamentals: All Metrics, Ratios and Statistics

VERTEX PHARMACEUTICALS INC

BIT:1VRTX (9/10/2025, 7:00:00 PM)

334.7

-2.05 (-0.61%)

Chartmill FA Rating
GICS SectorHealth Care
GICS IndustryGroupPharmaceuticals, Biotechnology & Life Sciences
GICS IndustryBiotechnology
Earnings (Last)08-04
Earnings (Next)11-03
Inst Owners97.63%
Inst Owner ChangeN/A
Ins Owners0.13%
Ins Owner ChangeN/A
Market Cap85.81B
Revenue(TTM)11.42B
Net Income(TTM)3.64B
Analysts75.9
Price Target416.5 (24.44%)
Short Float %N/A
Short RatioN/A
Dividend
Industry RankSector Rank
Dividend Yield N/A
Yearly DividendN/A
Dividend Growth(5Y)N/A
DPN/A
Div Incr YearsN/A
Div Non Decr YearsN/A
Ex-DateN/A
Surprises & Revisions
EPS beat(2)1
Avg EPS beat(2)-1.87%
Min EPS beat(2)-7.2%
Max EPS beat(2)3.45%
EPS beat(4)2
Avg EPS beat(4)-0.78%
Min EPS beat(4)-7.2%
Max EPS beat(4)3.69%
EPS beat(8)5
Avg EPS beat(8)-64.35%
EPS beat(12)7
Avg EPS beat(12)-42%
EPS beat(16)10
Avg EPS beat(16)-30.64%
Revenue beat(2)1
Avg Revenue beat(2)-2.37%
Min Revenue beat(2)-4.8%
Max Revenue beat(2)0.06%
Revenue beat(4)2
Avg Revenue beat(4)-0.57%
Min Revenue beat(4)-4.8%
Max Revenue beat(4)2.68%
Revenue beat(8)3
Avg Revenue beat(8)-0.87%
Revenue beat(12)5
Avg Revenue beat(12)-0.45%
Revenue beat(16)8
Avg Revenue beat(16)0.05%
PT rev (1m)-5.11%
PT rev (3m)-11.39%
EPS NQ rev (1m)0.02%
EPS NQ rev (3m)1.8%
EPS NY rev (1m)0.71%
EPS NY rev (3m)-0.04%
Revenue NQ rev (1m)0.39%
Revenue NQ rev (3m)1.43%
Revenue NY rev (1m)0.43%
Revenue NY rev (3m)0.22%
Valuation
Industry RankSector Rank
PE 23.19
Fwd PE 18.76
P/S 8.82
P/FCF 28.78
P/OCF 26.18
P/B 5.86
P/tB 6.43
EV/EBITDA 20.39
EPS(TTM)14.43
EY4.31%
EPS(NY)17.84
Fwd EY5.33%
FCF(TTM)11.63
FCFY3.47%
OCF(TTM)12.78
OCFY3.82%
SpS37.95
BVpS57.08
TBVpS52.02
PEG (NY)0
PEG (5Y)N/A
Graham NumberN/A
Profitability
Industry RankSector Rank
ROA 15.13%
ROE 21.18%
ROCE 22.25%
ROIC 16.69%
ROICexc 24.57%
ROICexgc 27.69%
OM 38.77%
PM (TTM) 31.86%
GM 86.11%
FCFM 30.65%
ROA(3y)10.62%
ROA(5y)14.47%
ROE(3y)13.73%
ROE(5y)19.12%
ROIC(3y)18.67%
ROIC(5y)19.24%
ROICexc(3y)46.18%
ROICexc(5y)52.12%
ROICexgc(3y)66.07%
ROICexgc(5y)80.93%
ROCE(3y)24.89%
ROCE(5y)25.65%
ROICexgc growth 3Y-29.98%
ROICexgc growth 5Y-9.76%
ROICexc growth 3Y-22.64%
ROICexc growth 5Y-1.94%
OM growth 3Y2.79%
OM growth 5Y6.75%
PM growth 3YN/A
PM growth 5YN/A
GM growth 3Y-0.74%
GM growth 5Y-0.17%
F-Score6
Asset Turnover0.48
Health
Industry RankSector Rank
Debt/Equity 0
Debt/FCF 0
Debt/EBITDA 0
Cap/Depr 173.52%
Cap/Sales 3.04%
Interest Coverage 260.41
Cash Conversion 83.13%
Profit Quality 96.21%
Current Ratio 2.52
Quick Ratio 2.16
Altman-Z N/A
F-Score6
WACC9.67%
ROIC/WACC1.73
Cap/Depr(3y)171.61%
Cap/Depr(5y)187.83%
Cap/Sales(3y)3.11%
Cap/Sales(5y)3.32%
Profit Quality(3y)N/A
Profit Quality(5y)N/A
High Growth Momentum
Growth
EPS 1Y (TTM)7966.67%
EPS 3Y-71.86%
EPS 5Y-44.14%
EPS Q2Q%135.23%
EPS Next Y6256.61%
EPS Next 2Y749.77%
EPS Next 3Y329.69%
EPS Next 5Y150.73%
Revenue 1Y (TTM)10.46%
Revenue growth 3Y13.31%
Revenue growth 5Y21.5%
Sales Q2Q%12.06%
Revenue Next Year10.03%
Revenue Next 2Y9.8%
Revenue Next 3Y9.48%
Revenue Next 5Y10.01%
EBIT growth 1Y4.24%
EBIT growth 3Y16.47%
EBIT growth 5Y29.7%
EBIT Next Year816.11%
EBIT Next 3Y130.8%
EBIT Next 5Y68.38%
FCF growth 1Y-9.77%
FCF growth 3YN/A
FCF growth 5YN/A
OCF growth 1Y-5.45%
OCF growth 3YN/A
OCF growth 5YN/A

VERTEX PHARMACEUTICALS INC / 1VRTX.MI Fundamental Analysis FAQ

Can you provide the ChartMill fundamental rating for VERTEX PHARMACEUTICALS INC?

ChartMill assigns a fundamental rating of 7 / 10 to 1VRTX.MI.


What is the valuation status for 1VRTX stock?

ChartMill assigns a valuation rating of 6 / 10 to VERTEX PHARMACEUTICALS INC (1VRTX.MI). This can be considered as Fairly Valued.


How profitable is VERTEX PHARMACEUTICALS INC (1VRTX.MI) stock?

VERTEX PHARMACEUTICALS INC (1VRTX.MI) has a profitability rating of 7 / 10.


What is the earnings growth outlook for VERTEX PHARMACEUTICALS INC?

The Earnings per Share (EPS) of VERTEX PHARMACEUTICALS INC (1VRTX.MI) is expected to grow by 6256.61% in the next year.